Page 1

C CLINUVEL 11 COMPANY ANNOUNCEMENT CLINUVEL REPORTS TENTH CONSECUTIVE HALF YEAR NET PROFIT Melbourne , Australia , 24 February 2021 KEY HIGHLIGHTS , HALF YEAR ENDED 31 DECEMBER 2020 ASX : XETRA - DAX : NASDAQ INTERNATIONAL DESIGNATION : Consolidated Entity Total Revenues Total Expenses Net Profit before income tax Basic Earnings per share Profit after income tax expense Net Tangible Assets backing per share Result $ 15,743,000 Change from same period 2019 Up 58 % $ 9,621,000 Up 5 % $ 5,811,000 $ 6,487,000 Up 852 % Up 962 % $ 0.133 $ 1.481 Up 956 % Up 10 % All figures reported in Australian dollars . Refer to the Appendix 4D Half Year Report released to the Australian Securities Exchange for details . CLINUVEL today announced its tenth consecutive half year net profit , released in its Half Yearly Report for the six months ended 31 December 2020. The Company achieved revenues for the period of $ 15.743 million and posted a half year net profit before tax of $ 5.811 million . " CLINUVEL's long - term strategy and focus has been reaffirmed by today's results , " CLINUVEL'S Chief Financial Officer , Mr Darren Keamy said . “ Despite ongoing global economic uncertainty , our team has expanded distribution of our lead drug SCENESSEⓇ in both the USA and Europe through our efficient business model and by exercising financial restraint and control . " The Company is in a sound financial position to continue to grow and fund its expansion . We are investing in our R & D and clinical programs and progressing our evolution into a diversified pharmaceutical company , ” Mr Keamy said . COMMERCIAL AND CLINICAL PROGRESS AND GROWTH CLINUVEL continues to strengthen its business despite the operating challenges of the pandemic and the world's largest economic contraction since the Great Depression in 1929 . During the December 2020 half year period , CLINUVEL increased access to its drug SCENESSE® ( afamelanotide 16mg ) 1 for patients with the rare metabolic disorder , erythropoietic Page 1 CUV UR9 CLVLY